Immunovalent Therapeutics is a precision medicine company harnessing microfluidic technology to revolutionize the treatment of cancer immunotherapy. Immunotherapy treatments have proven successful in the treatment of cancer by stimulating the immune system to destroy tumors.
While immunotherapy treatments have proven to be effective in treating some malignant disease, their benefits are unfortunately limited to a subset of patients. Significant efforts to identify appropriate biomarkers to guide treatment choices and provide predictive data have fallen short of the needs of practicing clinicians.
Cancer immunotherapy is a rapidly growing field and includes a variety of approaches that attempt to augment the innate ability of our immune system to recognize cancer cells as non-self or foreign and destroy them. Monitoring this dynamic process is very challenging, and there is no standardized or proven approach. Recently, checkpoint inhibitors have expanded their therapeutic range, now carrying FDA approvals for the treatment of melanoma, merkel cell carcinoma, lung cancer, urothelial cancer, renal cell cancer, Hodgkin lymphoma, head and neck squamous cell cancer, and microsatellite unstable tumors. Biomarkers will be crucial to the implementation, proper patient selection and monitoring of immunotherapy for this growing population of cancer patients.
The IMV assay leverages the innate ability of the immune system to recognize tumor as foreign and evaluates a potential simple and effective biomarker capable of monitoring the actual interaction between tumor and T-cell in a directly observable manner—this is unique among all currently available approaches.
To best monitor active immune responses, the interaction between tumor and immune system would ideally be modeled and monitored in real time, ex vivo. Such dynamic evaluation of immune lymphocyte and tumor cell interaction would provide personalized immune monitoring, and allow an accurate assessment of ongoing immune activity – response or nonresponse, guiding clinicians in the management of individual patients. Immunovalent (IMV) is an early stage biotechnology company that has developed technology that simplifies the process of isolating and monitoring targeted T-cell populations utilizing a microfluidic device as the means to differentiate tumor-specific and non-specific T-cell populations. This allows monitoring of active immune responses utilizing peripheral blood and sampled tumor tissue.